Rani Therapeutics (RANI) UBS Global Healthcare Conference 2024 summary

Platform overview and technology

• Focuses on oral delivery of biologics using the proprietary RaniPill capsule, aiming to replace subcutaneous and IV injections.

• Demonstrated comparable bioavailability to injectables in 15 preclinical and 3 clinical studies.

• Holds nearly 500 patents, supporting a strong intellectual property position.

• RaniPill can deliver 200 microliters of aqueous solution, expanding its applicability to over 90 drug candidates.

• Technology is drug and therapeutic agnostic, enabling partnerships across early-stage and on-market products.

Patient and physician insights

• 76% of patients on twice-yearly injections and 80% on biweekly injections prefer a daily oral pill.

• Nearly 40% of surveyed patients admit to skipping injections due to needle aversion.

• 81% of endocrinologists would initiate therapy sooner if an oral option were available.

• Oral delivery is consistently preferred by both patients and physicians, regardless of dosing frequency.

Pipeline and strategic partnerships

• RT-114 is a newly announced obesity program, developed in partnership with ProGen, featuring a 50/50 co-development and co-commercialization agreement.

• RT-114 uses PG-102, a GLP-1/GLP-2 dual agonist, with potential best-in-class efficacy and tolerability.

• RT-111 is a biosimilar Stelara (ustekinumab) program, with successful phase I results showing 84% bioavailability and no serious adverse events.

• Dosing schemes for RT-111 may allow for monthly or three-times-per-month oral dosing, potentially improving convenience and efficacy.